The present invention relates to analytical devices and processes, and more particularly, to devices and processes that incorporate electromagnetic write-heads and magneto-resistive read-sensors to detect target antigens.
It is known that antibodies bind with antigens as part of the human disease defense system. Presently, antigens are detected by such techniques as immunofluorescence, immunoperoxidase, or enzyme-linked immunosorbent assay (ELISA), each of which then employs a microscope for visual detection of the target antigen. It is desirable to exploit the use of magnetic signaling technology to automate the detection of analytes, such as antigens, and to further apply this technology to the detection of any biological matter.
Described are embodiments of an invention for a sample assembly with trenches for detection of analytes with electromagnetic read heads. The sample assembly includes an outer layer with at least one sample trench. The sample trench includes a first set of antibodies that are bonded on a first surface of a base layer. Target antigens are bonded with the first set of antibodies, and a second set of antibodies are bonded to the target antigens. Further, the sample trench includes nanoparticles that are bonded to the second set of antibodies. A head module includes a write head for magnetizing nanoparticles and a read sensor for detecting the magnetized nanoparticles, and thus, the target antigens. The sample trench constrains the biological sample, and thus the target antigen, during the preparation and subsequent analysis of the biological sample. Accordingly, the target antigen is aligned with read elements of a head module such that the target antigen is reliably and accurately detected. Further, to ensure reliable and accurate detection, the outer layer is formed with a low friction material allowing the read head to remain in contact with the upper surface of the outer layer during the process of detection.
For example, a method of forming a sample assembly of a biological sample having target antigens includes forming at least one sample trench within an outer layer, such that the sample trench has a bottom surface. Further, a base layer is formed and a first set of antibodies are bonded on a first surface of the base layer within the sample trench. The sample trench having the first set of bonded antibodies is exposed to a biological sample having target antigens. The target antigens bond with the first set of antibodies within the sample trench. A second set of antibodies are bonded to nanoparticles. In one embodiment the first and second set of antibodies are biologically identical. Further, the target antigens within the sample trench are exposed to the second set of antibodies that are bonded with the nanoparticles. The second set of antibodies bond with the target antigens within the sample trench.
In one embodiment, the method includes forming a plurality of magnetic servo alignment marks on the sample assembly. The method of forming the plurality of magnetic servo alignment marks includes forming at least one servo alignment trench in the outer layer parallel to the sample trench. Further, the step of forming the plurality of magnetic servo alignment marks includes filling the servo alignment trench with tape ink, curing the tape ink and forming the plurality of magnetic servo alignment marks in the cured tape ink.
In one embodiment, the method includes magnetizing the nanoparticles. Further, the nanoparticles are magnetized by a write head. In one embodiment, the base layer is formed on the bottom surface of the sample trench. In another embodiment, the outer layer is formed on the base layer and the base layer is exposed by the bottom surface of the sample trench.
In one embodiment the outer layer is selected from the group consisting of diamond-like-carbon, polytetrafluoroethylene, aluminum oxide, and polyamides. The first set of antibodies are bonded to the target antigen with a bonding material selected from the group consisting of amide, self-assembled-monolayers (SAMS), alkoxysilane, organic functional trialkoxysilane, and thiol containing surface modifiers.
In an embodiment of detecting target antigens in a biological sample on a sample assembly, the method includes forming at least one sample trench within an outer layer, such that the sample trench has a bottom surface. Further, a base layer is formed and a first set of antibodies are bonded on a first surface of the base layer within the sample trench. The sample trench having the first set of bonded antibodies is exposed to a biological sample having target antigens. The target antigens bond with the first set of antibodies within the sample trench. A second set of antibodies are bonded to nanoparticles. In one embodiment, the first and second set of antibodies are biologically identical. Further, the target antigens within the sample trench are exposed to the second set of antibodies that are bonded with the nanoparticles. The second set of antibodies bond with the target antigens within the sample trench. A head module is swept over the sample assembly. The head module includes at least one magneto-resistive read sensor to detect the target antigens.
In an embodiment of a sample assembly including a biological sample having a target antigen, the sample assembly includes an outer layer having at least one sample trench. The sample trench has a bottom surface. The sample assembly also includes a base layer. The sample trench includes a first set of antibodies bonded on a first surface of the base layer. The sample trench further includes target antigens which are bonded with the first set of antibodies. Further the sample trench includes a second set of antibodies which are bonded to the target antigens and nanoparticles bonded to the second set of antibodies. The first and second set of antibodies are biologically identical.
For a fuller understanding of the present invention, reference should be made to the following detailed description taken in conjunction with the accompanying drawings.
The present invention is described in exemplary embodiments in the following description with reference to the Figures, in which like numbers represent the same or similar elements. While the invention is described in terms of the best mode for achieving the invention's objectives, it will be appreciated by those skilled in the art that variations may be accomplished in view of these teachings without deviating from the spirit or scope of the invention.
Described are embodiments of an invention for a sample assembly with trenches for detection of analytes with electromagnetic read heads. The sample assembly includes an outer layer with at least one sample trench. The sample trench includes a first set of antibodies that are bonded on a first surface of a base layer. Target antigens are bonded with the first set of antibodies, and a second set of antibodies are bonded to the target antigens. Further, the sample trench includes nanoparticles that are bonded to the second set of antibodies. A head module includes a write head for magnetizing nanoparticles and a read sensor for detecting the magnetized nanoparticles, and thus, the target antigens. The sample trench constrains the biological sample, and thus the target antigen, during the preparation and subsequent analysis of the biological sample. Accordingly, the target antigen is aligned with read elements of a head module such that the target antigen is reliably and accurately detected. Further, to ensure reliable and accurate detection, the outer layer is formed with a low friction material allowing the read head to remain in contact with the upper surface of the outer layer during the process of detection.
An outer layer 253 is formed over substrate 199. Deposition techniques utilized herein include, but are not limited to, photolithography, silk-screening, and other similar processes. The outer layer may comprise diamond-like-carbon (DLC), polytetrafluoroethylene, aluminum oxide, polyamides, or other low-friction materials known in the art. The outer layer 253 may be formed to a thickness of between 0.2 to 60 microns. The outer layer 253 includes sample trenches 180. The process of forming the sample trenches 180 is described with respect to
One embodiment of forming sample trenches 180 is illustrated in
Another embodiment of forming sample trenches 180 is described with respect to
As shown in
In one embodiment, as shown in
In this embodiment, sample trenches 180 are masked and the servo alignment trench 194 is filled with tape ink. The tape ink, which contains magnetic recording particles in a polymer matrix, is cured by methods known in the art. Magnetic encoded servo alignment marks 193 are subsequently encoded in the cured tape ink.
In another embodiment, magnetic encoded servo alignment marks 193 are encoded on a piece of magnetic tape which is adhered to outer layer 253. Further, the magnetic encoded servo alignment marks 193 may be encoded by the manufacturer of substrate 199 on the magnetic tape. Magnetic encoded servo alignment marks 193 may be in the form of timing based servo marks as taught by U.S. Pat. No. 7,639,448 and entitled “Differential Timing Based Servo Pattern for Magnetic-Based Storage Media,” which is hereby incorporated by reference in its entirety. Servo alignment marks 193 are read by read sensor 106 and used to keep the write elements 108 and read sensors 106 in alignment with sample trenches 180 along the X-axis while the head module 104 moves relative to sample trenches 180 along the Y-axis.
Still further, in one embodiment the alignment marks 193 may be non-magnetic marks. For example, the alignment marks may be lithographed, silk-screened or ink jet printed, and read with an optical laser.
The sample trenches 180 include a biological sample having a target antigen. Sample trenches 180 act to constrain the biological sample, and thus the target antigen 210, during the preparation and subsequent analysis of the biological sample, as discussed below. For example, the sample trenches 180 prevent the biological sample from being rinsed away during a rinse step. Further, the sample trenches 180 allow the biological sample and the target antigen to be constrained to an area that is aligned with read elements 108, such that detection of target antigen 210 is reliably and accurately detected.
The preparation of the biological sample with target antigens 210 within the sample trench 180 is discussed further with respect to
In step 404, antibodies 208A are bonded within sample trenches 180 to the first surface of base layer 252. The antibodies 208A may be bonded within the sample trenches to the base layer 252 via bonds 206A such as amide, self-assembled-monolayers (SAMS), alkoxysilane, organic functional trialkoxysilane, thiol bonds, or the like. It is important to note that the material of base layer 252 facilitates the bonding of antibody 208A within sample trench 180.
In one embodiment, it is preferred that bond 206A is applied only to the first surface of base layer 252. In one example, the bonding comprises first coating base layer 252 with amide, self-assembled-monolayers (SAMS), alkoxysilane, or thiol and then placing a solution of antibodies 208A on substrate 199 and gently rocking substrate 199 for a period of time, up to six hours. Amide refers to organic compounds that include the functional group including an acyl group, with the chemical notation C═O, linked to a nitrogen (N) atom. A SAM is an organized layer of amphiphilic molecules in which one end of the molecule, the “head group,” shows a special affinity for gold, silicon, or SiO2, such as that utilized in base layer 252. At the terminal end, the opposite end of the SAM from the “head group” is a functional group. In one embodiment, the first set of antibodies 208A are attached to this functional group in step 404. Lastly, a thiol is a compound that includes the functional group composed of a sulfur atom and a hydrogen atom (—SH). Being the sulfur analog of an alcohol group (—OH), this functional group is referred to either as a thiol group or a mercaptan group.
There are generally five known isotopes (types) of antibodies 208A and 208B for mammals. In
In one embodiment, step 404 may include a step of rinsing substrate 199 with water or another rinsing agent to remove any antibodies 208A that are not bonded within sample trenches 180. In all rinsing steps discussed herein a surfactant may be added to the water or rinsing agent to reduce surface tension. In one example, the surfactant may include a detergent solution.
In step 406, antibodies 208A bonded within sample trench 180 are exposed to a biological sample including target antigens 210. In one example, this is accomplished by placing a blood sample or other biological sample on substrate 199. As shown in
Target antigens 210 may comprise cancer cells, viruses, or bacteria. In one embodiment, the target antigens 210 are viruses such as Human Papilloma Virus (HPV) which is known to lead to cancer. It is important to note that the antibodies 208A utilized in step 404 are specifically chosen based on the targeted antigens 210 utilized in step 406.
In step 408, a second set of antibodies 208B are bonded with nanoparticles 212. It is important to note that the first set of antibodies 208A and the second set of antibodies 208B are biologically identical, as both bond to the same target antigen 210. In one embodiment, the second set of antibodies 208B are bonded with nanoparticles 212 in parallel with steps 404 and 406. In other embodiments, the second set of antibodies 208B may be bonded with nanoparticles 212 before or after steps 404 and 406. The nanoparticles 212 include a magnetic inner core 216 and a outer shell 214. Magnetic inner cores 216 may comprise hard magnetic materials with high coercivity, such as Fe2O3, CrO2, and Barium Ferrite BaFe. For example, magnetic inner cores 216 may comprise iron oxide based nanoparticle materials, including M Fe2O4 (where M may be Co, Ni, Cu, Zn, Cr, Ti, Ba, or Mg) nanomaterials, and iron oxide coated nanoparticle materials or other structures with similar functionality.
In one embodiment, step 408 further includes preparing the nanoparticles 212 prior to bonding the nanoparticles 212 to antibodies 208A. The preparation of nanoparticles 212 is described in
In another embodiment, the step of demagnetizing the inner cores 216 of nanoparticles may be omitted. The process of manufacturing the inner cores 216 of nanoparticles may include a step of high temperature sintering. Thus, the manufacturing process of the nanoparticles 212 may demagnetize the inner cores 216. The formation of nanoparticles is taught without limitation by U.S. Pat. No. 6,962,685, entitled “Synthesis of Magnetite Nanoparticles and the Process of Forming,” which is hereby incorporated by reference in its entirety.
Returning to
In step 410, target antigens 210 are exposed to the second set of antibodies 208B bonded to nanoparticles 212. This may be done by placing a solution of nanoparticle-labeled antibodies 208B on substrate 199. As shown in
In the embodiment in which substrate 199 is a Peltier substrate, the process may include an optional step of applying a DC voltage of a first polarity to the Peltier substrate. Applying a DC voltage of a first polarity heats the surface of the substrate 199 and dries the biological sample within the sample trench 180. A DC voltage of a second and opposite polarity may be applied to Peltier substrate, to cool the surface of the substrate. In an alternate embodiment, the Peltier substrate freezes the biological sample.
Returning to
As mentioned above, the sample trenches 180 may have spacing from one sample trench to the adjacent sample trench along the X-axis to match the spacing from one read sensor 108 to the adjacent read sensor 108 along the X-axis. In one embodiment the spacing between one sample trench 180 and an adjacent sample trench 180 is 166.5 microns to match the read sensor to read sensor spacing of the IBM® TS1130 tape drive.
Write-heads 106 may be any write head known in the art. In one embodiment write-heads 106 comprise miniature electromagnets, with a coil sandwiched between two poles. Read-sensors 108 may be anisotropic magneto-resistive (AMR), giant magneto-resistive (GMR), or tunnel magneto-resistive (TMR) read-sensors, or other devices with similar functionality known in the art. GMR read-sensors, which are also known as spin-valve read-sensors, typically have an internal anti-parallel pinned layer for increased sensitivity. TMR read-sensors may utilize a tunnel barrier layer to augment the GMR internal structure and to provide increased sensitivity.
As shown in
Head module 104 is kept in linear alignment with sample trenches 180 along the X-axis by position-error-servo (PES) read-head 192, which reads magnetically encoded servo-alignment marks 193 from servo track 194 on sample assembly 100. PES read-head 192 may be, for example, an AMR, GMR, or TMR read-sensor. In the example illustrated in
In step 412 of
In one embodiment, the head module 104 comes into physical contact with the upper surface 254 of the outer layer 253 during the sweeping step of 412. Keeping the head module 104 in physical contact with the upper surface ensures that the head module 104 is kept at a known Z-axis position and assists with alignment of head module 104 with sample trenches 180. As discussed above, the outer layer 253 may comprise diamond-like-carbon, polytetrafluoroethylene, aluminum oxide, polyamides, or other low-friction materials known in the art. Accordingly, the low friction material of the outer layer assists the head module 104 to smoothly sweep the sample trenches 180 while in physical contact with the upper surface 254 of outer layer 253, such that the target antigens of the biological sample is reliably and accurately detected.
As discussed with respect to step 502 in
Write head 106 magnetizes inner cores 216 of nanoparticles 212 along the Y-axis, which is the longitudinal direction of recording in the tape drive industry. Read-sensor 108 magnetically detects nanoparticles 212 along the Y-axis. As a result in step 412, the nanoparticles 212 may be magnetized by write-head 106 and then immediately and magnetically detected by read-sensor 108 during a single sweep of the sample trenches 180. As discussed above, this process is referred to as a read-after-write operation. In one embodiment, the write-head 106 and read-sensor 108 are separated by a magnetic shield (not shown) to prevent cross-talk between write-head 106 and read-sensor 108 during step 412.
Alternatively, the steps of magnetizing nanoparticles 212 and the step of detecting the nanoparticles 212 may be performed separately. For example, write head 106 magnetizes inner cores 216 of nanoparticles 212 along the Y-axis of sample assembly 100. In one embodiment, write-head 106 is then turned off. Subsequently, read-sensor 108 magnetically detects nanoparticles 212 along the Y-axis. The read module sensor 108 may be swept across sample trenches 180 along the Y-axis in both the +Y and −Y directions. Accordingly, read-sensor 108 can repeatedly check for magnetized nanoparticles 212, thus ensuring that all target antigens 210 are detected.
In an embodiment in which the number of sample trenches 180 are greater than the number of write-head 106 and read-sensor 108 pairs in head module 104, the head module 104 may scan the sample trenches 180 in a serpentine fashion. The head module 104 performs a scan in the +Y direction, as head module 104 only provides read-after-write capability in the +Y direction as shown in
The coercivity of a magnetic inner core 216 may be chosen selectively depending upon the target antigen 210 to be detected. For example, nanoparticles 212 with magnetic inner cores 216 of different coercivity values may be respectively bonded to different types of antibodies 208A and 208B to detect various types of target antigens 210 on the sample assembly 100 simultaneously. Nanoparticles 212 may have different magnetic properties associated with each antigen-antibody combination. Read-sensor 108 detects the different magnetic properties of an inner core 216 based on the materials used for that inner core 216. As discussed above, magnetic inner cores 216 may comprise hard magnetic materials with high coercivity, such as Fe2O3, CrO2, and Barium Ferrite BaFe. For example, magnetic inner cores 216 may comprise iron oxide based nanoparticle materials, including M Fe2O4 (where M may be Co, Ni, Cu, Zn, Cr, Ti, Ba, or Mg) nanomaterials, and iron oxide coated nanoparticle materials or other structures with similar functionality. As a result, in step 412, read-sensor 108 may detect more than one type of target antigens 210 with a single sweep of the sample assembly 100.
Processor 602 sends signals to power amplifier 704. Power amplifier provides power to write-head 106 for magnetizing nanoparticles 212. Processor 602 also sends signals to power amplifier 716. Power amplifier 716 powers Wheatstone bridge 706. In one embodiment, Wheatstone bridge includes read-sensor 108. Thus, read-sensor receives DC current from the Wheatstone bridge 706. Read-sensor 108 detects a resistance change during step 412 discussed above. The resistance change is based on the magnetic field provided by the magnetized inner cores 216 of nanoparticles 212. Wheatstone bridge 706 balances out the zero-magnetism resistance of read-sensor 108 such that only the change in resistance of read-sensor 108 is sent to amplifier 714. The amplifier 714 receives the change in resistance and sends the change in resistance to processor 602 through filter 718. Filter 718 filters out noise. In one embodiment, filter 718 filters out 60 Hz noise which is the type of noise that is pervasive in an office or laboratory setting in which processes of the invention may be performed.
Processor 602 includes a matched filter 730 and a table 720. Processor 602 determines if a nanoparticle 212 was detected, and thus, if a target antigen 210 has been detected. The change in resistance of read-sensor 108 is directly proportional to the magnetic field provided by nanoparticle 212. The change in resistance of read-sensor 108 is directly proportional to the magnetic field provided by nanoparticle 212.
As discussed above, the coercivity of a magnetic inner core 216 may be chosen selectively depending upon the target antigen 210 to be detected. For example, nanoparticles 212 with magnetic inner cores 216 of different coercivity values may be respectively bonded to different types of antibodies 208A and 208B to detect various types of target antigens 210 on the sample assembly 100 simultaneously. The identification of the target antigens 210 in the sample trenches 180 may be facilitated by a lookup table 720 in processor 602. In one embodiment, the lookup table 720 includes a list of (a) target antigens 210, (b) the antibodies 208A and 208B bonded with the target antigens 210, and (c) the coercivity of the inner cores 216 of nanoparticles 212 bonded to antibodies 208B.
In one embodiment of the invention a correlation calculation is performed by the write and read circuit of
C(y)=∫g(η)h(η−y)dη Equation[1]
In equation [1], η is the integration variable along the Y-axis that varies as read-sensor 108 sweeps along the Y-axis. The matched filter 730 includes an impulse response h(y) of an ideal signal profile of a detected target nanoparticle 212. Since h(y) is used repetitively, it may be calculated once and stored as matched filter 730 in processor 602.
The range of correlation C(y) is between −1 and +1, where +1 represents an ideal correlation of one hundred percent (100%), and −1 indicates no correlation. The electrical waveform g(y) of each potential detection of a nanoparticle 212 by read-sensor 108 has its correlation C(y) calculated in step 412 of
In one embodiment, the results of the sweep of step 412 may be displayed to a physician or clinician to inform the physician or clinician of the presence (or absence) of target antigens 210 in the biological sample. The results may include items such as the target antigen(s) tested for, the types of antibodies used, a simple positive-detection or negative-detection indication for each antigen, the number of nanoparticles detected for each antigen to give an indication of the prevalence of the targeted antigen, and the number of rejected detections based on the correlation calculation.
The terms “certain embodiments”, “an embodiment”, “embodiment”, “embodiments”, “the embodiment”, “the embodiments”, “one or more embodiments”, “some embodiments”, and “one embodiment” mean one or more (but not all) embodiments unless expressly specified otherwise. The terms “including”, “comprising”, “having” and variations thereof mean “including but not limited to”, unless expressly specified otherwise. The enumerated listing of items does not imply that any or all of the items are mutually exclusive, unless expressly specified otherwise. The terms “a”, “an” and “the” mean “one or more”, unless expressly specified otherwise.
Devices that are in communication with each other need not be in continuous communication with each other, unless expressly specified otherwise. In addition, devices that are in communication with each other may communicate directly or indirectly through one or more intermediaries. Additionally, a description of an embodiment with several components in communication with each other does not imply that all such components are required. On the contrary a variety of optional components are described to illustrate the wide variety of possible embodiments.
Further, although process steps, method steps, algorithms or the like may be described in a sequential order, such processes, methods and algorithms may be configured to work in alternate orders. In other words, any sequence or order of steps that may be described does not necessarily indicate a requirement that the steps be performed in that order. The steps of processes described herein may be performed in any order practical. Further, some steps may be performed simultaneously, in parallel, or concurrently.
While particular embodiments of the present invention have been shown and described, it will be obvious to those skilled in the art that, based upon the teachings herein changes and modification may be made without departing form this invention and its broader aspects and, therefore, the appended claims are to encompass within their scope all such changes and modifications as are within the true spirit and scope of this invention. Furthermore, it is to be understood that the invention is solely defined by the appended claims.
Number | Name | Date | Kind |
---|---|---|---|
2376965 | Hellkvist | May 1945 | A |
2948624 | Watson et al. | Aug 1960 | A |
3823276 | Maslowski et al. | Jul 1974 | A |
4062047 | Scull | Dec 1977 | A |
4292920 | Smith et al. | Oct 1981 | A |
4708931 | Christian | Nov 1987 | A |
5005096 | Krounbi et al. | Apr 1991 | A |
5146004 | Morris et al. | Sep 1992 | A |
5189571 | Murphy et al. | Feb 1993 | A |
5206159 | Cohen et al. | Apr 1993 | A |
5206590 | Dieny et al. | Apr 1993 | A |
5331493 | Schwarz | Jul 1994 | A |
5376965 | Nagasaki et al. | Dec 1994 | A |
5452164 | Cole et al. | Sep 1995 | A |
5465185 | Heim et al. | Nov 1995 | A |
5615065 | Cheung | Mar 1997 | A |
5661039 | Kung et al. | Aug 1997 | A |
5689384 | Albrecht et al. | Nov 1997 | A |
5689394 | Esser et al. | Nov 1997 | A |
5736349 | Sasaki et al. | Apr 1998 | A |
5764567 | Parkin | Jun 1998 | A |
5840889 | Cavalieri et al. | Nov 1998 | A |
5863507 | James | Jan 1999 | A |
5922537 | Ewart et al. | Jul 1999 | A |
5948624 | Rothschild et al. | Sep 1999 | A |
5965375 | Valkirs | Oct 1999 | A |
6013531 | Wang et al. | Jan 2000 | A |
6021013 | Albrecht et al. | Feb 2000 | A |
6027946 | Weitschies et al. | Feb 2000 | A |
6282051 | Albrecht et al. | Aug 2001 | B1 |
6320719 | Albrecht et al. | Nov 2001 | B1 |
6432346 | Hall | Aug 2002 | B1 |
6462904 | Albrecht et al. | Oct 2002 | B1 |
6493172 | Morris et al. | Dec 2002 | B1 |
6548311 | Knoll | Apr 2003 | B1 |
6643084 | Andrew et al. | Nov 2003 | B1 |
6736978 | Porter et al. | May 2004 | B1 |
6770489 | Enpuku | Aug 2004 | B1 |
6962685 | Sun | Nov 2005 | B2 |
7153366 | Chen et al. | Dec 2006 | B1 |
7342738 | Anderson et al. | Mar 2008 | B1 |
7556863 | Berning et al. | Jul 2009 | B2 |
7639448 | Haustein et al. | Dec 2009 | B2 |
7639488 | Tu | Dec 2009 | B2 |
7649708 | Winarski et al. | Jan 2010 | B2 |
7649709 | Winarski et al. | Jan 2010 | B2 |
7679858 | Winarski et al. | Mar 2010 | B2 |
7960184 | Morozov et al. | Jun 2011 | B2 |
8694280 | Awezec et al. | Apr 2014 | B2 |
9034660 | Boday et al. | May 2015 | B2 |
9081004 | Boday et al. | Jul 2015 | B2 |
9304130 | Boday et al. | Apr 2016 | B2 |
9435800 | Bates | Sep 2016 | B2 |
10132804 | Bates et al. | Nov 2018 | B2 |
20020001960 | Wu et al. | Jan 2002 | A1 |
20020030044 | Brown | Mar 2002 | A1 |
20020119470 | Nerenberg et al. | Aug 2002 | A1 |
20020174453 | Daniell et al. | Nov 2002 | A1 |
20030077616 | Lomas | Apr 2003 | A1 |
20030077642 | Fritsch et al. | Apr 2003 | A1 |
20030186465 | Kraus et al. | Oct 2003 | A1 |
20040002125 | Gombrich et al. | Jan 2004 | A1 |
20040061968 | Fukushima et al. | Apr 2004 | A1 |
20040080855 | Tsuchiya et al. | Apr 2004 | A1 |
20040132220 | Fish | Jul 2004 | A1 |
20040166508 | Pawlak et al. | Aug 2004 | A1 |
20040219361 | Cui et al. | Nov 2004 | A1 |
20040219631 | Yokozeki et al. | Nov 2004 | A1 |
20050087000 | Coehoorn et al. | Apr 2005 | A1 |
20050100930 | Wang et al. | May 2005 | A1 |
20060020371 | Ham et al. | Jan 2006 | A1 |
20060040273 | Chaiken et al. | Feb 2006 | A1 |
20060051237 | Wang et al. | Mar 2006 | A1 |
20060128035 | Coehoorn et al. | Jun 2006 | A1 |
20060216696 | Goguen | Sep 2006 | A1 |
20070054154 | Leu | Mar 2007 | A1 |
20070115578 | Winarski et al. | May 2007 | A1 |
20070146715 | Potyrailo et al. | Jun 2007 | A1 |
20070146925 | Haustein et al. | Jun 2007 | A1 |
20080012119 | Otremba et al. | Jan 2008 | A1 |
20080036450 | Kahlman et al. | Feb 2008 | A1 |
20080206104 | Prins et al. | Aug 2008 | A1 |
20080226917 | Zhong et al. | Sep 2008 | A1 |
20090021856 | Winarski et al. | Jan 2009 | A1 |
20090027801 | Winarski et al. | Jan 2009 | A1 |
20090047520 | Lee et al. | Feb 2009 | A1 |
20090066318 | Kahlman et al. | Mar 2009 | A1 |
20090072815 | Kahlman et al. | Mar 2009 | A1 |
20090104707 | Wang et al. | Apr 2009 | A1 |
20090152657 | Suh et al. | Jun 2009 | A1 |
20090170212 | Van Der Wijk et al. | Jul 2009 | A1 |
20090212768 | Llandro et al. | Aug 2009 | A1 |
20090243594 | Kahlman | Oct 2009 | A1 |
20090268325 | Iben et al. | Oct 2009 | A1 |
20090273857 | Iben et al. | Nov 2009 | A1 |
20090314066 | Nieuwenhuis et al. | Dec 2009 | A1 |
20100017922 | Shin et al. | Jan 2010 | A1 |
20100021708 | Kong et al. | Jan 2010 | A1 |
20100093119 | Shimizu | Apr 2010 | A1 |
20100147003 | Ueda et al. | Jun 2010 | A1 |
20110053289 | Lowe et al. | Mar 2011 | A1 |
20110070440 | Linhardt et al. | Mar 2011 | A1 |
20110076670 | Boday et al. | Mar 2011 | A1 |
20110076726 | Lakey et al. | Mar 2011 | A1 |
20110076782 | Awezec et al. | Mar 2011 | A1 |
20110077869 | Boday et al. | Mar 2011 | A1 |
20110077902 | Awezec et al. | Mar 2011 | A1 |
20110262955 | Licher et al. | Oct 2011 | A1 |
20110293940 | Tokoro et al. | Dec 2011 | A1 |
20120157330 | Boday et al. | Jun 2012 | A1 |
20120164717 | Irudayaraj | Jun 2012 | A1 |
20120280675 | Berman et al. | Nov 2012 | A1 |
20120283976 | Berman et al. | Nov 2012 | A1 |
20140080118 | Bates et al. | Mar 2014 | A1 |
20160223533 | Boday et al. | Aug 2016 | A1 |
20160274099 | Bates | Sep 2016 | A1 |
20160274102 | Bates | Sep 2016 | A1 |
Number | Date | Country |
---|---|---|
1454851 | Nov 2003 | CN |
1783219 | Jun 2006 | CN |
1967660 | May 2007 | CN |
101509919 | Aug 2009 | CN |
101558313 | Oct 2009 | CN |
101632018 | Jan 2010 | CN |
2073016 | Jun 2009 | EP |
2005010542 | Feb 2005 | WO |
2006047840 | May 2006 | WO |
2008102218 | Aug 2008 | WO |
2009039437 | Mar 2009 | WO |
2009083856 | Jul 2009 | WO |
2009157739 | Dec 2009 | WO |
Entry |
---|
Non-Final Office Action from U.S. Appl. No. 13/616,855, dated Nov. 20, 2015. |
Boday et al., U.S. Appl. No. 12/970,837, filed Dec. 16, 2010. |
Restriction Requirement from U.S. Appl. No. 12/970,837, dated Jan. 29, 2013. |
Non-Final Office Action from U.S. Appl. No. 12/970,837, dated May 10, 2013. |
Final Office Action from U.S. Appl. No. 12/970,837, dated Nov. 22, 2013. |
Notice of Allowance from U.S. Appl. No. 12/970,837, dated Jan. 8, 2015. |
Bates et al., U.S. Appl. No. 13/616,855, filed Sep. 14, 2012. |
Non-Final Office Action from U.S. Appl. No. 13/616,855, dated Jun. 4, 2013. |
Non-Final Office Action from U.S. Appl. No. 13/616,855, dated Dec. 30, 2013. |
Final Office Action from U.S. Appl. No. 13/616,855, dated Jul. 24, 2014. |
Office Action from German Application No. 112011104401.1, dated May 13, 2015. |
Chinese Office Action from Application No. 201180060053.7 dated Jun. 27, 2014. |
International Search Report and Written Opinion from International Application No. PCT/EP2011/070578, dated Mar. 19, 2012. |
Awezec et al., U.S. Appl. No. 12/888,394, filed Sep. 22, 2010. |
Awezec et al., U.S. Appl. No. 12/888,403, filed Sep. 22, 2010. |
Boday et al., U.S. Appl. No. 12/888,408, filed Sep. 22, 2010. |
Boday et al., U.S. Appl. No. 12/888,388, filed Sep. 22, 2010. |
Crowther, J., “The ELISA Guidebook,” Humana Press, Totowa, New Jersey, 2001, pp. 1-425. |
Fox et al., “Tear and Serum Antibody Levels in Ocular Herpetic Infection: Diagnostic Precision of Secretory IgA,” British Journal of Ophthalmology, vol. 70, 1986, pp. 584-588. |
Liu et al., “Discrimination of specific and non-specific bindings by dielectrophoretic repulsion in on-chip magnetic bioassays,” Journal of Biosensors and Bioelectronics, No. 24, 2009, pp. 2294-2297. |
Llandro et al., “Magnetic biosensor technologies for medical applications: a review,” Med. and Biol. Eng. and Computing, Springer Berlin, Jun. 15, 2010, 22 Pages. |
Millen et al., “Giant Magenetoresistive Sensors. 2. Detection of Biorecognition Events at Self-Referencing and Magnetically Tagged Arrays”, Analytical Chemistry, vol. 80, No. 21, pp. 7940-7946, Nov. 1, 2008. |
Nordling et al., “Giant Magnetoresistance Sensors. 1. Internally Calibrated Readout of Scanned Magnetic Arrays,” Anal. Chem., vol. 80, 2008, pp. 7930-7939. |
Osterfeld et al., “Multiplex protein assays based on real-time magnetic nanotag sensing,” PNAS, vol. 105, No. 52. Dec. 30, 2008, pp. 20637-20640. |
Piedade et al., “A New Hand-Held Microsystem Architecture for Biological Analysis,” IEEE Trans. on Circuits and Systems—I: Regular Papers, vol. 53, No. 11, Nov. 2006, pp. 2384-2395. |
Schuurs et al., “Enzyme-Immunoassay,” Clini Chim Acta, vol. 81, 1977, pp. 1-40. |
Shen et al., “Detection of DNA labeled with magnetic nanoparticles using MgO-based magnetic tunnel junction sensors,” Journal of Applied Physics, vol. 103, 2008, pp. 07 A306-1-07 A306-3. |
Yammamoto et al., “Active immobilization of biomolecules on a hybrid three-dimensional nanoelectrode by dielectrophoresis for single-biomolecule study,” Nanotechnology, vol. 18,2007,495503, pp. 1-7. |
Statement of Relevance of Non-Translated Foreign Document WO2009157739. |
Notice of Allowance from U.S. Appl. No. 13/616,855, dated Mar. 15, 2016. |
Boday et al., U.S. Appl. No. 15/096,175, filed Apr. 11, 2016. |
Supplemental Notice of Allowance from U.S. Appl. No. 13/616,855, dated Apr. 19, 2016. |
Bates et al., U.S. Appl. No. 15/169,340, filed May 31, 2016. |
Bates et al., U.S. Appl. No. 15/169,479, filed May, 31, 2016. |
Awezec et al., U.S. Appl. No. 61/246,329, filed Sep. 28, 2009. |
Final Office Action from U.S. Appl. No. 13/099,360, dated Feb. 25, 2014. |
Non-Final Office Action from U.S. Appl. No. 13/099,360, dated Oct. 1, 2013. |
Notice of Allowance from U.S. Appl. No. 13/099,358, dated Sep. 15, 2014. |
Notice of Allowance from U.S. Appl. No. 13/099,360, dated Jun. 4, 2014. |
Restriction Requirement from U.S. Appl. No. 13/099,358, dated Jun. 20, 2014. |
Advisory Action from U.S. Appl. No. 12/888,388, dated Jul. 25, 2013. |
Final Office Action from U.S. Appl. No. 12/888,388, dated May 9, 2013. |
Notice of Allowance from U.S. Appl. No. 12/888,388, dated Jan. 12, 2015. |
Non-Final Office Action from U.S. Appl. No. 12/888,388, dated Jan. 7, 2013. |
Restriction Requirement from U.S. Appl. No. 12/888,388, dated Aug. 28, 2012. |
Non-Final Office Action from U.S. Appl. No. 12/888,394, dated Oct. 7, 2013. |
Restriction Requirement from U.S. Appl. No. 12/888,394, dated Dec. 10, 2012. |
Final Office Action from U.S. Appl. No. 12/888,403, dated Feb. 21, 2013. |
Notice of Allowance from U.S. Appl. No. 12/888,403, dated Nov. 22, 2013. |
Non-Final Office Action from U.S. Appl. No. 12/888,403, dated Jun. 14, 2013. |
Non-Final Office Action from U.S. Appl. No. 12/888,403, dated Sep. 20, 2012. |
Advisory Action from U.S. Appl. No. 12/888,408, dated Feb. 26, 2015. |
Final Office Action from U.S. Appl. No. 12/888,408, dated Dec. 10, 2014. |
Non-Final Office Action from U.S. Appl. No. 12/888,408 dated May 23, 2014. |
Non-Final Office Action from U.S. Appl. No. 15/169,479, dated Jan. 18, 2018. |
Notice of Allowance from U.S. Appl. No. 12/970,837, dated Jan. 7, 2016. |
Supplemental Notice of Allowance from U.S. Appl. No. 12/970,837, dated Mar. 1, 2016. |
Notice of Allowance from U.S. Appl. No. 15/169,479, dated Jul. 12, 2018. |
Restriction Requirement from U.S. Appl. No. 15/096,175, dated Jul. 27, 2018. |
Non-Final Office Action from U.S. Appl. No. 15/169,340, dated Jul. 27, 2018. |
Supplemental Notice of Allowance from U.S. Appl. No. 15/169,479, dated Aug. 15, 2018. |
Non-Final Office Action from U.S. Appl. No. 15/096,175, dated Dec. 27, 2018. |
Examination Report from European Application No. GB1312478.9, dated Nov. 28, 2018. |
Final Office Action from U.S. Appl. No. 15/169,340, dated Feb. 7, 2019. |
Notice of Allowance from U.S. Appl. No. 15/169,340, dated Apr. 18, 2019. |
Number | Date | Country | |
---|---|---|---|
20160018392 A1 | Jan 2016 | US |
Number | Date | Country | |
---|---|---|---|
Parent | 12970837 | Dec 2010 | US |
Child | 14869734 | US |